N-1-ethyl,N-3-(S)-1-phenylethyl urea | 19034-99-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-1-ethyl,N-3-(S)-1-phenylethyl urea
• 英文别名: 1-ethyl-3-[(1S)-1-phenylethyl]urea
• CAS: 19034-99-2
• 化学式: C₁₁H₁₆N₂O
• 分子量: 192.261
• InChiKey: MHLCAEJNLFIMGX-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  水合茚三酮 、 N-1-ethyl,N-3-(S)-1-phenylethyl urea 以 苯 为溶剂， 反应 1.0h， 以44%的产率得到1,3,3a,8a-tetrahydro-(3aS,8aR)-dihydroxy-1-ethyl, 3-((S)-1-phenylethyl)indeno-[1,2-d]-imidazole-2,8-dione
  参考文献：
  名称：

  Synthesis, resolution and anticonvulsant activity of chiral N-1′-ethyl,N-3′-(1-phenylethyl)-(R,S)-2′H,3H,5′H-spiro-(2-benzofuran-1,4′-imidazolidine)-2′,3,5′-trione diastereomers

  摘要：

  Four new N-1', N-3'-disubstituted-2'H, 3H, 5'H-spiro-(2-benzofuran-1,4'-imidazolidine)-2',3,5'-triones bearing a chiral N-3' substituent were synthesized, resolved and their anticonvulsant activity was obtained and determined that the activity was not stereoselective. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.005
• 作为产物：
  描述：

  (S)-(-)- α-甲基苄胺 、 异氰酸乙酯 以 四氢呋喃 为溶剂， 反应 1.0h， 以98%的产率得到N-1-ethyl,N-3-(S)-1-phenylethyl urea
  参考文献：
  名称：

  Synthesis, resolution and anticonvulsant activity of chiral N-1′-ethyl,N-3′-(1-phenylethyl)-(R,S)-2′H,3H,5′H-spiro-(2-benzofuran-1,4′-imidazolidine)-2′,3,5′-trione diastereomers

  摘要：

  Four new N-1', N-3'-disubstituted-2'H, 3H, 5'H-spiro-(2-benzofuran-1,4'-imidazolidine)-2',3,5'-triones bearing a chiral N-3' substituent were synthesized, resolved and their anticonvulsant activity was obtained and determined that the activity was not stereoselective. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.005

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：EP2400846B1

  公开（公告）日：2016-10-05
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：Qiu Yao-Ling

  公开号：US20100233122A1

  公开（公告）日：2010-09-16

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• LINKED DIBENZIMIDAZOLE ANTIVIRALS
  申请人：Qiu Yao-Ling

  公开号：US20100266543A1

  公开（公告）日：2010-10-21

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US20140341851A1
  申请人：——

  公开号：US20140341851A1

  公开（公告）日：2014-11-20
• US8101643B2
  申请人：——

  公开号：US8101643B2

  公开（公告）日：2012-01-24